ISRCTN63089812 : A ten week randomised, double-blind, parallel-group, placebo-controlled phase II study to investigate the extent of symptom relief and the safety and tolerability of SMP-986 (20 mg, 40 mg, 80 mg and 120 mg) administered once daily for eight weeks to patients with overactive bladder syndrome
- Overall trial status
- Completed
- Recruitment status
- No longer recruiting
Latvia
Urological and Genital Diseases